The European Medicines Agency (EMA) has published a new document titled 'FAQs: Supervise a Clinical Trial: Inspection records - CTIS Training Programme - Module 16', dated 4 May 2026. The document provides answers to frequently asked questions regarding the handling of inspection records within the Clinical Trial Information System (CTIS), targeting sponsors, investigators, and regulatory authorities involved in clinical trial supervision.
The FAQs, part of the CTIS Training Programme Module 16, clarify procedures for uploading, accessing, and managing inspection-related documents in CTIS. They address practical issues such as which documents constitute inspection records, how to ensure data completeness, and the roles of different users in the inspection process. The guidance is non-binding but aims to harmonise practices across EU member states.
Document type and purpose
The document is a guidance document, not a regulation or mandatory standard. It serves as a training aid to support the implementation of the Clinical Trials Regulation (EU) No 536/2014, which mandates the use of CTIS for all clinical trial applications in the EU. The FAQs supplement earlier training modules and reflect feedback from stakeholders on common challenges encountered during inspections.
Policy orientations and trade-offs
The FAQs emphasise transparency and standardisation of inspection records, which can increase regulatory oversight but may impose additional administrative burdens on sponsors, particularly small and medium-sized enterprises. By clarifying expectations, the guidance aims to reduce inconsistencies in how inspection records are submitted across member states, potentially speeding up regulatory reviews. However, the detailed requirements could lead to higher compliance costs for trial sponsors, who must ensure their systems align with CTIS specifications.
Impact on stakeholders
- Sponsors (pharmaceutical companies, biotech firms): They face moderate impact due to the need to adapt internal processes to meet the clarified record-keeping standards. The FAQs reduce ambiguity but require investment in training and system updates.
- National competent authorities: They benefit from more uniform inspection data, facilitating cross-border collaboration and oversight. The guidance supports efficient supervision but may require additional training for inspectors.
- Investigators and clinical trial sites: They experience minor impact as the FAQs primarily address sponsor and authority responsibilities, though they may need to coordinate with sponsors on record provision.
- Patients: Indirectly, improved inspection record management can enhance trial integrity and patient safety, but no direct impact is expected.
Expected institutional follow-up
The FAQs are part of EMA's ongoing CTIS training programme. Further modules and updates are anticipated as the system evolves. EMA may revise the FAQs based on user feedback and emerging inspection practices. The document does not signal any immediate regulatory changes but reinforces the agency's commitment to supporting the effective use of CTIS.